HCPLive Five at ESC 2024

With 32,000 participants representing over 170 nations, the ESC Congress 2024 in London, England showcased its status as a leading event in cardiology and broader medical fields. Featuring 4,400 new abstracts and 112 studies published concurrently in medical journals, the congress provided a stage for presenting groundbreaking research and advancements that could influence cardiovascular disease management and prevention practices for years to come.

As part of our conference coverage, the HCPLive Cardiology team was on-site in London conducting interviews and live coverage. In this edition of the HCPLive Five, we recap our video interviews related to coverage of ESC Congress 2024, including videos centered around finerenone in heart failure, the role of semaglutide in reducing CV risk, and high-impact clinical trials at the meeting.

Don't Miss a Beat: Finerenone's Role in Heart Failure from ESC Congress Data

Live from ESC Congress 2024!

In this edition of Don’t Miss a Beat, Stephen Greene, MD, an advanced heart failure specialist at Duke University School of Medicine, discusses the prospect of finerenone in treatment algorithms for heart failure with Muthiah Vaduganathan, MD, MPH, codirector of the Center for Cardiometabolic Implementation Science of Brigham and Women’s Hospital, based on data from the meeting, including FINEARTS-HF, FINE-HEART, and an analysis on MRA use in heart failure.

FLOW: Semgalutide Provides Consistent CV Benefit Across Spectrum of Kidney Disease

In this video, Kenneth Mahaffey, MD, professor of Medicine at Stanford University, discusses an analysis of the FLOW trial assessing the effects of the GLP-1 receptor agonist using different definitions of kidney disease severity. The article provides a summary of the data presented at the ESC Congress 2024, specifically the effects on cardiovascular death, myocardial infarction, and stroke among patient groups stratified by baseline chronic kidney disease severity.

SEQUOIA-HCM Substudy Details Effects of Aficamten on Cardiac Structure and Remodeling

One of 3 video interviews from our ESC Congress coverage featuring Ahmad Masri, MD, MS, director of the Hypertrophic Cardiomyopathy Center at Oregon Health & Science University, the subject of this segment are the results of a SEQUOIA-HCM substudy leveraging cardiac magnetic resonance to assess structural changes associated with aficamten use in hypertrophic cardiomyopathy.

ESC Congress Recap: High-Impact Clinical Trials, with Deepak Bhatt, MD, MPH, MBA

In a follow-up to our conference preview interview with him, our editorial team sat down with Deepak Bhatt, MD, MPH, MBA, director of Mount Sinai Heart and the Dr. Valentin Foster Professor of Cardiovascular Medicine at the Icahn School of Medicine, for his post-conference perspective on the meeting’s top trials and new data releases. In the discussion Bhatt highlights a group of 4 studies from the meeting: FINEARTS-HF, ABYSS, RESHAPE-HF2, and SHAM-PVI.

Kausik Ray, MD, MPhil: INTERASPIRE and the Expanding Knowledge Base for Lipoprotein(a)

In this video, Kausik Ray, MD, MPhil, professor of Public Heath, director of the Imperial Centre for CVD Prevention, deputy director of Imperial Clinical Trials Unit and head of Commercial Trials at Imperial College London, discusses the results of the INTERASPIRE study and how it improves our understanding of the effects of elevated lipoprotein(a) [Lp(a)].

An international survey designed to assess Lp(a) levels in patients recently diagnosed with coronary heart disease across multiple countries and regions, INTERASPIRE leveraged data from 13 countries, including information related to testing methodologies, patient interviews and central lab analyses.